Decoy Therapeutics Inc. received a notice of effectiveness from the U.S. Securities and Exchange Commission (SEC) for its S-1 registration statement. This declaration allows the pre-clinical biotechnology company to proceed with its previously filed Initial Public Offering (IPO).
The registration statement establishes an equity financing facility. This effectiveness enables the company to begin selling shares to the public to secure essential capital.
Decoy Therapeutics develops peptide conjugate therapeutics for infectious diseases and oncology using a proprietary AI-powered platform. The company expects its existing cash reserves to fund operations only through late 2026.